Where to Buy Zepbound: Every Legal Purchase Channel, What Each Costs, and When Compounded Tirzepatide Makes More Sense

Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Zepbound is available only by prescription through three legal channels: retail pharmacies (CVS, Walgreens, etc.), mail-order pharmacies (Express Scripts, OptumRx), and telehealth platforms that connect you with prescribers and compounding pharmacies
• Brand-name Zepbound single-dose pens list at about $1,086 per month, but LillyDirect sells self-pay vials and KwikPens for $299 (2.5 mg), $399 (5 mg) or $449 (7.5 mg and up), and GoodRx lists the KwikPen at $299 at Walgreens, CVS, Walmart and Costco (September 2026); with commercial coverage and the Lilly savings card the copay can be as low as $25 per fill
• Compounded tirzepatide (the same active ingredient) had a month-1 median price of $299 (range $149 to $470 across 14 providers) in the FormBlends Compounded GLP-1 Price Index on September 3, 2026; it is not covered by insurance and requires no prior authorization
• You cannot legally buy Zepbound without a prescription from a licensed U.S. provider, and online pharmacies selling tirzepatide without requiring a prescription are operating illegally

The short answer

Zepbound is available by prescription at retail pharmacies (CVS, Walgreens, Rite Aid), mail-order pharmacies (Express Scripts, OptumRx), and through telehealth platforms that prescribe compounded tirzepatide. Brand-name Zepbound single-dose pens list at about $1,086 per month, but Lilly's own self-pay channel, LillyDirect, sells vials and KwikPens for $299 to $449 a month as of September 2026, and GoodRx lists the KwikPen at $299 at major chains. Compounded tirzepatide runs a median of $299 for the first month (range $149 to $470, FormBlends price index, September 3, 2026). Both require a prescription from a licensed provider. No legal over-the-counter option exists.

Table of contents

1. The three legal channels to buy Zepbound
2. What most articles get wrong about "buying Zepbound online"
3. Retail pharmacy: how to fill a Zepbound prescription at CVS, Walgreens, or local pharmacies
4. Mail-order pharmacy: Express Scripts, OptumRx, and insurance-based delivery
5. Telehealth platforms: the compounded tirzepatide pathway
6. Real costs: brand Zepbound vs compounded tirzepatide, with and without insurance
7. The Lilly savings card: who qualifies, how much it saves, and the hidden restrictions
8. Prior authorization: why your insurance requires it and how long it takes
9. When compounded tirzepatide is the better option (and when it's not)
10. The FDA shortage context: how compounding was legal during the shortage, and what applies now
11. International pharmacies and gray-market sources: why they're illegal and risky
12. The decision tree: which purchase channel fits your situation
13. Every way to buy Zepbound, September 2026
14. Compounding after the shortage
15. Counterfeit and research-use-only Zepbound
16. The 2026 savings card, corrected
17. KwikPen vs pen vs vial
18. FAQ
19. Sources

The three legal channels to buy Zepbound

Zepbound (tirzepatide) is a prescription medication approved by the FDA in November 2023 for chronic weight management. It is a prescription-only medication (not a DEA-scheduled controlled substance; the label carries no schedule), which means you cannot legally purchase it without a prescription from a licensed healthcare provider. An earlier version of this page called it Schedule V, which was wrong.

The three legal pathways are:

Channel 1: Retail pharmacies. CVS, Walgreens, Rite Aid, Kroger, Walmart, and independent pharmacies stock brand-name Zepbound. You bring a prescription from your doctor (or your doctor sends it electronically), the pharmacy submits a claim to your insurance, and you pick up the medication. This channel works best if you have commercial insurance with a weight-loss drug benefit and your plan approves Zepbound.

Channel 2: Mail-order pharmacies. Express Scripts, OptumRx, Caremark, and other pharmacy benefit managers (PBMs) offer 90-day supplies shipped to your home. Most insurance plans incentivize mail-order by charging lower copays (for example, $75 for a 90-day supply vs $50 per month at retail). This channel requires prior authorization in nearly all cases.

Channel 3: Telehealth platforms with compounded tirzepatide. Platforms like FormBlends, and others connect you with licensed providers who prescribe compounded tirzepatide (the same active ingredient as Zepbound) if clinically appropriate. The prescription is filled by a state-licensed compounding pharmacy and shipped to your home. This channel does not involve insurance, does not require prior authorization, and costs a flat monthly fee.

All three channels require a prescription. The difference is whether you're buying brand-name Zepbound (channels 1 and 2) or compounded tirzepatide (channel 3), and whether insurance is involved. Since 2025 there is effectively a fourth channel, Lilly's own LillyDirect self-pay program (home delivery or Walmart pickup), plus Amazon Pharmacy, Ro, Walgreens Weight Management and the Medicare GLP-1 Bridge; the September 2026 channel table below lists each one with its price.

What most articles get wrong about "buying Zepbound online"

Most articles conflate two entirely different things: buying brand-name Zepbound through a legitimate mail-order pharmacy vs buying compounded tirzepatide through a telehealth platform.

The common error is treating "online pharmacy" as a single category. It's not. There are four distinct types:

1. Legitimate mail-order pharmacies operated by PBMs. Express Scripts, OptumRx, and Caremark are licensed in all 50 states, contracted with insurance plans, and dispense FDA-approved brand-name Zepbound. These are legal and safe.

1. Telehealth platforms that prescribe compounded tirzepatide. FormBlends and similar platforms connect you with U.S.-licensed providers and U.S.-based compounding pharmacies. The medication is compounded tirzepatide, not brand-name Zepbound. This is legal under the FDA's compounding exemption during the tirzepatide shortage period.

1. International pharmacies selling tirzepatide without a prescription. These are illegal. Importing prescription drugs from foreign pharmacies violates the Federal Food, Drug, and Cosmetic Act. The FDA does not inspect these facilities, and there is no quality assurance.

1. Research chemical suppliers selling tirzepatide peptides. These are not pharmacies. They sell tirzepatide labeled "for research use only" to avoid FDA regulation. Injecting research-grade peptides is dangerous and illegal for human use.

The first two are legal. The second two are not. Articles that lump all four together as "buying Zepbound online" mislead readers into thinking legitimate telehealth compounding is equivalent to black-market peptide suppliers. It's not.

Retail pharmacy: how to fill a Zepbound prescription at CVS, Walgreens, or local pharmacies

If you have a prescription for brand-name Zepbound from your doctor, here's the process at a retail pharmacy:

Step 1: Prescription submission. Your provider sends the prescription electronically to your chosen pharmacy, or you bring a paper prescription. Zepbound is available in six doses (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg). The prescription specifies the dose and quantity (typically four pens per month, one injection per week).

Step 2: Insurance claim submission. The pharmacy submits a claim to your insurance. If your plan covers Zepbound and no prior authorization is required, the claim processes in minutes. If prior authorization is required (the common case), the pharmacy receives a rejection code and contacts your doctor to initiate the PA process.

Step 3: Prior authorization. Your doctor's office submits clinical documentation to your insurance company: your BMI, weight history, comorbidities (diabetes, hypertension, sleep apnea), and previous weight-loss attempts. The insurance company reviews the request. Approval takes 3 to 10 business days on average, but can extend to 30 days if additional documentation is requested.

Step 4: Copay determination. Once approved, your insurance assigns a copay based on your plan's formulary tier. Zepbound is typically Tier 3 (preferred brand) or Tier 4 (non-preferred brand). Copays vary widely by plan design; a specialty-tier copay can run several hundred dollars a month.

Step 5: Savings card application. If your copay is above $25, you can apply the Lilly savings card (see section below). Under the 2026 terms the card reduces out-of-pocket to as little as $25 per fill for commercially insured patients whose plan covers Zepbound, with a maximum benefit of $100 per one-month fill ($200 for two months, $300 for three) and $1,300 per calendar year across 13 fills.

Step 6: Pickup. You pick up the medication. Zepbound is shipped to pharmacies in refrigerated packaging and stored at 36 to 46°F. The pharmacy dispenses four single-dose pens per month.

The entire process takes 3 to 14 days from prescription to pickup if prior authorization is required. If your plan does not require PA (rare), you can pick up the medication the same day or next day.

Stock availability note. The FDA declared the tirzepatide shortage resolved on December 19, 2024. Spot shortages at an individual pharmacy still happen; if yours is out of a strength, ask about the KwikPen (four weekly doses in one pen), another pharmacy in the same chain, or LillyDirect home delivery. An earlier version of this note described intermittent starter-dose shortages as of April 2026, which we could not verify.

Mail-order pharmacy: Express Scripts, OptumRx, and insurance-based delivery

Mail-order pharmacies are operated by pharmacy benefit managers (PBMs) contracted with insurance companies. The three largest are Express Scripts (owned by Cigna), OptumRx (owned by UnitedHealth), and Caremark (owned by CVS Health).

How it works:

Your doctor sends the prescription to the mail-order pharmacy (or you transfer an existing prescription from retail). The pharmacy processes the insurance claim, completes prior authorization if needed, and ships a 90-day supply (12 pens) to your home in refrigerated packaging.

Cost advantage:

Most insurance plans charge lower copays for mail-order. For example:

• Retail: $150 copay per 30-day supply = $450 per 90 days
• Mail-order: $300 copay per 90-day supply = $150 savings

The Lilly savings card applies to mail-order prescriptions the same way it applies to retail, reducing out-of-pocket to $25 per 30-day equivalent ($75 per 90-day supply).

Timing:

First fill takes 7 to 14 days (including prior authorization and shipping). Refills take 3 to 5 days. The pharmacy ships in insulated packaging with gel ice packs. If you're not home when the package arrives, the medication remains cold for 24 to 48 hours.

When mail-order makes sense:

• You have insurance that covers Zepbound
• Your plan incentivizes mail-order with lower copays
• You're on a maintenance dose (not titrating frequently)
• You're comfortable with 90-day supplies shipped to your home

When it doesn't:

• You're titrating doses every 4 weeks (mail-order requires 90-day fills)
• Your insurance doesn't cover Zepbound
• You need the medication immediately (mail-order takes a week minimum)

Telehealth platforms: the compounded tirzepatide pathway

Telehealth platforms like FormBlends operate differently from retail and mail-order pharmacies. They do not dispense brand-name Zepbound. Instead, they connect you with licensed providers who prescribe compounded tirzepatide, which is prepared by a state-licensed compounding pharmacy.

How it works:

1. Online intake. You complete a medical intake form (height, weight, medical history, current medications, weight-loss goals). This takes 10 to 15 minutes.

1. Provider review. A licensed physician or nurse practitioner reviews your intake within 24 to 48 hours. If tirzepatide is clinically appropriate, they write a prescription for compounded tirzepatide.

1. Compounding and shipping. The prescription is sent to a compounding pharmacy (typically a 503A or 503B facility registered with the FDA). The pharmacy compounds the medication in a sterile environment, packages it with syringes and alcohol wipes, and ships it to your home in refrigerated packaging.

1. Ongoing care. You check in monthly or as needed. The provider adjusts your dose based on weight loss, side effects, and tolerance. Refills are automatic unless you pause or cancel.

What you receive:

A vial of compounded tirzepatide (typically 5 mg or 10 mg total per vial, divided into weekly doses), insulin syringes, alcohol prep pads, and a sharps container. You draw the dose yourself and inject subcutaneously once per week.

Cost:

Median $299 for the first month across 14 providers, range $149 to $470, per the Compounded GLP-1 Price Index on September 3, 2026; prices vary by dose and platform, and a few providers add a separate membership fee. No insurance accepted. No prior authorization required. Most prices include the medication, provider visits and shipping.

Legal basis:

Compounding is legal under Section 503A of the Federal Food, Drug, and Cosmetic Act when done in response to an individual prescription. The tirzepatide shortage that once shielded copies of the drug ended when the FDA declared it resolved on December 19, 2024; enforcement discretion for 503A pharmacies ended February 18, 2025 and for 503B outsourcing facilities on March 19, 2025. Compounded tirzepatide dispensed today rests on a patient-specific prescription from a licensed prescriber, not on the shortage. An earlier version of this paragraph said tirzepatide remained on the shortage list as of April 2026, which was wrong.

Real costs: brand Zepbound vs compounded tirzepatide, with and without insurance

The cost comparison depends on whether you have insurance, whether your insurance covers Zepbound, and whether you qualify for the Lilly savings card.

Scenario	Brand Zepbound (retail/mail-order)	Compounded tirzepatide (telehealth)
No insurance	$299 to $449/month via LillyDirect self-pay vial or KwikPen; about $1,086 list for single-dose pens	Median $299 for month 1 (range $149 to $470)
Commercial insurance, no coverage	$499/month with the 2026 Lilly savings card, or $299 to $449 via LillyDirect	Median $299 for month 1 (range $149 to $470)
Commercial insurance with coverage, before savings card	Your plan's copay (varies widely)	Median $299 for month 1 (range $149 to $470)
Commercial insurance with coverage, after Lilly savings card	As low as $25 per fill (card pays at most $100/$200/$300 per one-, two- or three-month fill, $1,300/year)	Median $299 for month 1 (range $149 to $470)
Medicare (Part D)	$50/month under the Medicare GLP-1 Bridge (KwikPen, July 1, 2026 to December 31, 2027, prior authorization); no savings card	Median $299 for month 1 (range $149 to $470)
Medicaid	Covered for obesity in 13 state programs as of January 2026 (KFF); low copay where covered	Median $299 for month 1 (range $149 to $470)

Key insight: If you have commercial insurance that covers Zepbound and you qualify for the Lilly savings card, brand-name Zepbound costs as little as $25 per fill, which is cheaper than compounded tirzepatide. Prices in the table are as of September 3 to 5, 2026. If you don't have insurance, or your insurance doesn't cover weight-loss medications, or you're on Medicare (which prohibits manufacturer copay cards), compounded tirzepatide is 50% to 70% cheaper than paying cash for brand Zepbound.

Hidden costs to consider:

• Brand Zepbound: Prior authorization takes time (3 to 30 days). If your insurance denies coverage, you pay full price or switch to compounded.
• Compounded tirzepatide: You draw and inject the medication yourself (takes 2 minutes per dose). Brand Zepbound uses pre-filled pens (30 seconds per dose). Some patients prefer pens; others don't mind syringes.

Pattern we see in FormBlends consultations: most patients who choose compounded tirzepatide do so for access reasons (a denied or slow prior authorization, or a plan that covers semaglutide but not tirzepatide) rather than because they have no insurance. An earlier version of this paragraph gave a percentage split; we have removed it because it was not audited against a dated sample.

The Lilly savings card: who qualifies, how much it saves, and the hidden restrictions

The Lilly Zepbound Savings Card is a manufacturer coupon that reduces out-of-pocket costs for commercially insured patients. It's the single most important cost factor if you're buying brand-name Zepbound.

Who qualifies:

• You have commercial (private) health insurance
• Your insurance covers Zepbound (even if it requires prior authorization)
• You are not enrolled in a government insurance program (Medicare, Medicaid, TRICARE, VA)
• You are 18 years or older

Who does NOT qualify:

• Medicare Part D enrollees (federal law prohibits manufacturer copay assistance for Medicare patients)
• Medicaid enrollees
• Uninsured patients paying cash
• Patients whose commercial plan does not cover Zepbound do not get the $25 price, but under the 2026 terms the card gives them a fixed $499 per one-month fill

How much it saves:

Under the 2026 terms (card expires December 31, 2026), the card brings your copay to as little as $25 per fill when your plan covers Zepbound. The maximum benefit is $100 per one-month fill, $200 per two-month fill or $300 per three-month fill, with a cap of $1,300 per calendar year across 13 fills. An earlier version of this section described a $550 monthly benefit, which was the 2024 card.

Example:

• Your insurance copay: $125/month
• Lilly card benefit: $100/month (the one-month maximum)
• Your final out-of-pocket: $25/month

If your insurance copay is $300/month:

• Lilly card benefit: $100/month (the maximum)
• Your final out-of-pocket: $200/month, which is why people with high copays now compare LillyDirect self-pay at $299 to $449 instead

Annual maximum:

The card covers up to $1,300 per calendar year across a maximum of 13 fills.

How to get it:

Visit Zepbound.com and click "Savings & Support." Download the card or save it to your phone. Present it to the pharmacist when you pick up your prescription. The pharmacist applies the discount at the point of sale.

The hidden restriction most articles miss:

The $25 price only applies if your insurance covers Zepbound. If your commercial plan denies coverage or excludes weight-loss drugs, the 2026 card instead sets a flat $499 price per one-month fill. If you have no insurance at all, the card does not apply; LillyDirect self-pay ($299 to $449) is the route for cash-pay patients.

This is the single most common point of confusion. Patients assume the card works like a discount coupon at a grocery store (apply it to the full price and get a fixed amount off). It doesn't. When your plan covers Zepbound it reduces the copay after the claim is processed, and when your commercial plan does not cover it, it sets the $499 price.

If your insurance denies coverage, your options are:

1. Appeal the denial (takes 30 to 60 days, success rate varies)
2. Buy self-pay Zepbound through LillyDirect at $299 to $449/month, or use the card's $499 not-covered price at a retail pharmacy
3. Switch to compounded tirzepatide (median $299 for month 1 (range $149 to $470, FormBlends price index, September 3, 2026))

Prior authorization: why your insurance requires it and how long it takes

Prior authorization (PA) is an insurance company's way of controlling costs for expensive medications. Instead of automatically approving every prescription, the insurer requires your doctor to submit clinical documentation proving the medication is medically necessary.

Why insurers require PA for Zepbound:

Zepbound costs $12,720 per year at list price. Insurers want to ensure it's prescribed only to patients who meet clinical criteria (BMI ≥30, or BMI ≥27 with weight-related comorbidities) and who have tried other weight-loss interventions first (diet, exercise, and sometimes other medications like phentermine or naltrexone-bupropion).

What the PA process requires:

Your doctor submits:

• Your current BMI and weight
• Documentation of weight-related comorbidities (type 2 diabetes, hypertension, sleep apnea, dyslipidemia, cardiovascular disease)
• Records of previous weight-loss attempts (diet programs, exercise plans, other medications)
• A letter of medical necessity explaining why Zepbound is appropriate

Some insurers also require:

• A minimum BMI threshold (30 or 27 with comorbidities)
• Proof of 6 to 12 months of supervised weight-loss attempts
• Exclusion of other causes of obesity (hypothyroidism, Cushing's syndrome)

How long it takes:

• Fast track: 3 to 5 business days if all documentation is complete and the request meets clear criteria
• Standard: 7 to 10 business days for most requests
• Slow track: 14 to 30 days if the insurer requests additional documentation or peer-to-peer review (your doctor talks to the insurer's medical director)

Approval rates:

Published data from 2024 (Conti et al., JAMA Health Forum) shows that 60% to 70% of initial PA requests for GLP-1 weight-loss medications are approved. About 20% are denied and later approved on appeal. About 10% to 20% are denied and remain denied.

Common denial reasons:

• BMI below the plan's threshold
• Insufficient documentation of previous weight-loss attempts
• The plan excludes all weight-loss medications from coverage
• The plan covers semaglutide (Wegovy) but not tirzepatide (Zepbound) and requires step therapy (try Wegovy first)

What to do if denied:

1. Ask why. The denial letter will state the reason. Common reasons are fixable (missing documentation, wrong ICD-10 code).
2. Appeal. Your doctor can submit additional documentation or request a peer-to-peer review. Appeals take 30 to 60 days.
3. Switch medications. If your plan covers Wegovy but not Zepbound, ask your doctor about switching to semaglutide.
4. Switch to compounded. Compounded tirzepatide does not require insurance or prior authorization.

When compounded tirzepatide is the better option (and when it's not)

Compounded tirzepatide makes sense in five situations:

1. Your insurance doesn't cover weight-loss medications at all. Many plans exclude all obesity drugs from the formulary. If your plan has a blanket exclusion, your two cash routes are LillyDirect self-pay Zepbound ($299 to $449 a month) and compounded tirzepatide (median $299 for month 1 (range $149 to $470, FormBlends price index, September 3, 2026)); brand single-dose pens list at about $1,086.

2. Your prior authorization was denied and appeals failed. If your insurer denies coverage and you've exhausted appeals, compounded is the path forward.

3. You're on Medicare. Medicare Part D plans are not required to cover weight-loss medications, and most don't. Even if your plan covers Zepbound, you cannot use the Lilly savings card (federal law prohibits manufacturer copay assistance for Medicare patients). Your out-of-pocket could be $500+/month. Compounded tirzepatide is cheaper.

4. You need to start immediately. Prior authorization takes 3 to 30 days. Compounded tirzepatide platforms like FormBlends can get medication to you in 3 to 5 days from intake to delivery.

5. You prefer the flexibility of telehealth. Some patients prefer not dealing with insurance, pharmacies, and prior authorization paperwork. Compounded platforms handle everything (provider visit, prescription, compounding, shipping) in one workflow.

When brand Zepbound is the better option:

1. You have commercial insurance that covers Zepbound and you qualify for the Lilly savings card. $25 per fill is cheaper than any cash option. If you can get brand Zepbound for $25 a fill, that's the best deal available.

2. You prefer pre-filled pens over drawing doses yourself. Zepbound pens are easier and faster. Compounded tirzepatide requires drawing the dose from a vial with a syringe. It's not difficult (takes 2 minutes), but some patients prefer the convenience of pens.

3. You want FDA-approved medication. Brand Zepbound is FDA-approved. Compounded tirzepatide is not (compounded medications are exempt from FDA approval requirements). For some patients, FDA approval provides peace of mind.

The steelman case against compounded tirzepatide:

Compounded medications are not subject to the same manufacturing oversight as FDA-approved drugs. The FDA inspects compounding pharmacies, but less frequently than commercial drug manufacturers. There have been cases of contamination, incorrect dosing, and sterility failures at compounding pharmacies (though these are rare and usually involve 503B outsourcing facilities, not 503A pharmacies).

If you have access to brand-name Zepbound at an affordable price, the FDA-approved product is the safer choice from a regulatory oversight perspective. Compounded tirzepatide is a reasonable alternative when brand access is blocked by cost or insurance, but it's not equivalent to brand-name medication in terms of regulatory scrutiny.

That said, state-licensed 503A compounding pharmacies have a strong safety record overall. The risk is low but non-zero. Patients should weigh the cost savings against the marginal increase in risk.

The FDA shortage context: how compounding was legal during the shortage, and what applies now

Correction, September 2026: this section previously said tirzepatide remained on the FDA shortage list as of April 2026 and that the FDA gives 60 to 90 days' notice before removing a drug. Neither was true. The FDA declared the tirzepatide injection shortage resolved on December 19, 2024. Its enforcement discretion for compounders then wound down on a published schedule: February 18, 2025 for 503A pharmacies and March 19, 2025 (90 days from the memo) for 503B outsourcing facilities.

What that means for buyers in 2026: compounding of a drug that is essentially a copy of an approved product is no longer shielded by shortage status. Compounded tirzepatide that is still dispensed rests on a patient-specific prescription from a licensed prescriber and a state-licensed pharmacy, and the FDA has kept counting problems. As of May 31, 2026 it had received 990 adverse-event reports involving compounded semaglutide and more than 730 involving compounded tirzepatide, and on August 27, 2026 the Fifth Circuit upheld the FDA's semaglutide shortage-resolution decision.

Practically: if you buy compounded tirzepatide, buy it from a platform whose prescriber and pharmacy you can name and whose pharmacy license you can verify with the state board, and keep the FDA's unapproved-GLP-1 page bookmarked. The FDA no longer lists tirzepatide as in shortage, so a seller who tells you compounding is legal because of the shortage is out of date by more than a year.

International pharmacies and gray-market sources: why they're illegal and risky

Some patients consider buying tirzepatide from international online pharmacies, especially Canadian or Indian pharmacies that ship to the U.S. This is illegal and risky.

Why it's illegal:

The Federal Food, Drug, and Cosmetic Act prohibits importing prescription drugs from foreign countries except in very narrow circumstances (personal importation for serious conditions with no U.S. treatment option, and even then only with FDA approval). Tirzepatide does not qualify.

Buying from an international pharmacy violates federal law. The medication can be seized by U.S. Customs and Border Protection. You can be fined. The pharmacy is not licensed in the U.S. and operates outside FDA jurisdiction.

Why it's risky:

• No quality assurance. The FDA does not inspect foreign pharmacies. You have no way to verify the medication is real tirzepatide, correctly dosed, or sterile.
• Counterfeit risk. Counterfeit GLP-1 medications are a documented problem. The FDA's warnings have kept coming. On February 26, 2025 it sent a warning letter to USApeptide.com for selling unapproved, misbranded semaglutide and tirzepatide labeled "research use only" without prescriptions, and as of May 31, 2026 it had logged 990 adverse-event reports for compounded semaglutide and more than 730 for compounded tirzepatide. Lilly's counterfeit page says counterfeit and research-grade tirzepatide is sold online, on social media and at med-spas, and cites the National Association of Boards of Pharmacy estimate that only about 5% of roughly 35,000 online pharmacies comply with U.S. pharmacy law. We found no FDA alert specific to counterfeit Zepbound pens as of September 5, 2026; the FDA's counterfeit alerts to date concern Ozempic.
• No recourse. If the medication is contaminated, misdosed, or causes harm, you have no legal recourse. The pharmacy is outside U.S. jurisdiction.

Research chemical suppliers:

Some websites sell tirzepatide labeled "for research use only" or "not for human consumption." These are not pharmacies. They sell peptides intended for laboratory research, not human injection. The peptides are not manufactured under sterile conditions, not tested for purity, and not safe for human use.

Injecting research-grade peptides is dangerous. An earlier version of this paragraph cited a 2022 case series that we could not locate, and it has been removed. What the regulators have said is enough: per the FDA, as relayed on Lilly's counterfeit page, counterfeit products may contain the wrong ingredients, or too much, too little or no active ingredient, and the FDA's February 2025 warning letter noted that research-use-only semaglutide and tirzepatide were sold with no prescription and without the boxed thyroid-tumor warning. Lilly asks patients to report suspected counterfeit product at 1-800-545-5979.

The bottom line: Stick to the three legal channels (retail pharmacies, mail-order pharmacies, and telehealth platforms with U.S.-licensed compounding pharmacies). The cost savings from international or gray-market sources are not worth the legal and medical risks.

The decision tree: which purchase channel fits your situation

Start here: Do you have health insurance?

No: LillyDirect self-pay Zepbound or compounded tirzepatide via telehealth. LillyDirect sells Zepbound vials and KwikPens for $299 to $449 a month with no insurance involved, with home delivery or Walmart pickup; compounded tirzepatide had a month-1 median of $299 (range $149 to $470) on September 3, 2026. Brand single-dose pens at list price (about $1,086) are the expensive route almost nobody needs to take.

Yes → Does your insurance cover weight-loss medications (Zepbound, Wegovy, Saxenda)?

No: LillyDirect self-pay Zepbound or compounded tirzepatide. If your plan excludes obesity drugs, insurance won't help. Your two cash routes are LillyDirect ($299 to $449 a month, brand Zepbound) and compounded tirzepatide (median $299 for month 1 as of September 3, 2026); the savings card's $499 not-covered price is a third, usually more expensive, option.

Yes → Are you on Medicare or Medicaid?

Medicare: check the GLP-1 Bridge and your Part D formulary. From July 1, 2026 through December 31, 2027 the Medicare GLP-1 Bridge prices the Zepbound KwikPen at $50 a month for eligible beneficiaries with prior authorization (healthinsurance.org). Outside the Bridge, Part D plans can cover Zepbound for obstructive sleep apnea and Mounjaro for type 2 diabetes but not for weight loss alone. The Lilly savings card cannot be used with Medicare.

Medicaid → Check your state's formulary. Some states cover Zepbound for patients with diabetes but not for weight loss alone. If covered, your copay is $0 to $10/month. If not covered, switch to compounded.

Commercial insurance → Does your plan require prior authorization for Zepbound?

No (rare) → Fill at retail or mail-order pharmacy. Apply the Lilly savings card. Your out-of-pocket will be $25/month. This is the cheapest option.

Yes (common) → Start the prior authorization process. While waiting (3 to 30 days), you can either:

• Wait for approval, then fill at retail/mail-order with the Lilly savings card ($25/month)
• Start compounded tirzepatide (median $299 for month 1 (range $149 to $470, FormBlends price index, September 3, 2026)) or LillyDirect self-pay Zepbound ($299 to $449) immediately and switch to the covered brand if and when PA is approved

If PA is denied → Appeal or switch to compounded. If the appeal fails, compounded tirzepatide is your path forward.

Every legitimate way to buy Zepbound in September 2026, with what each costs

The channel list on this page was written when the only cash route was the pharmacy counter at list price. That is no longer the market. These are the sellers that hold the first page of Google for this search and what each charged on September 4 and 5, 2026.

Channel	What you get	Price	Notes
LillyDirect (Lilly's own self-pay program)	Zepbound single-dose vials or multi-dose KwikPen, home delivery or pickup at about 4,600 Walmart pharmacies	$299 (2.5 mg), $399 (5 mg), $449 (7.5 to 15 mg)	The $449 tier requires a refill within 45 days of the last delivery; otherwise $499 for 7.5 mg and $699 for 10 to 15 mg. No insurance involved. Walmart pickup launched mid-November 2025.
Retail pharmacy with a GoodRx coupon	Zepbound KwikPen	$299	Listed at Walgreens, CVS, Walmart, Costco, HEB, Sam's Club and Target on September 5, 2026; GoodRx says that is 50% off its average retail figure of $600.38. Cannot be combined with insurance.
Retail or mail-order pharmacy with commercial insurance	Zepbound single-dose pens (the insurance-billed product, list about $1,086)	Your copay, as low as $25 per fill with the Lilly savings card	Card pays at most $100, $200 or $300 per one-, two- or three-month fill, $1,300 a year, 13 fills; commercially insured but not covered: $499 a month. Expires December 31, 2026.
Ro	Zepbound KwikPen, shipped direct	$299 / $399 / $449 by dose, plus membership from $74 a month on annual prepay	Same Lilly tiers and 45-day refill rule; KwikPen holds four weekly doses.
Walgreens Weight Management	Zepbound KwikPen through a Lilly offer	$299 (2.5 mg), $399 (5 mg), $499 (7.5 mg), $699 (10 mg and up); $49 per video visit, no subscription	Self-pay patients only; offer runs through December 31, 2026. Walgreens shows the non-45-day price for 7.5 mg and up.
Amazon Pharmacy	Zepbound KwikPen, brand only	From $299 a month cash, per GLP Chart (August 31, 2026)	Amazon's product page returned only navigation to our fetch, so the price is second-hand. New patients go through a One Medical visit.
TrumpRx.gov	Zepbound vials	Routed to LillyDirect; site advertises up to 72% off list	The government portal does not sell the drug; Lilly manages all Zepbound vial orders through LillyDirect (Customer Care 844-559-3471).
WeightWatchers Med+	Prescription plus LillyDirect cash-pay Zepbound	$25 a month for two months then $74 a month, plus $299 / $399 / $449 for the drug	WW states the KwikPen is not eligible for insurance coverage; delayed-refill prices $599 to $1,049.
Medicare GLP-1 Bridge	Zepbound KwikPen for eligible Medicare beneficiaries	$50 a month	July 1, 2026 to December 31, 2027; prior authorization; outside the $2,100 Part D cap.
Compounded tirzepatide via telehealth	Compounded vials, not FDA-approved	Median $299 for month 1, range $149 to $470 across 14 providers	FormBlends Compounded GLP-1 Price Index, September 3, 2026; see the Compounded GLP-1 Price Index. For FormBlends' own price, see the product page and the index.

One pattern across the table: every legitimate cash channel for brand Zepbound now lands at $299 for the starting dose, because they all resolve to Lilly's self-pay tiers. What differs is the fee on top (Ro's membership, Walgreens' $49 visits, WW's $74) and whether you get a pen or a vial.

Compounding after the shortage: what changed on December 19, 2024 and what the FDA has counted since

The FDA declared the tirzepatide injection shortage resolved on December 19, 2024. The same notice set the end of enforcement discretion for compounders at February 18, 2025 for state-licensed 503A pharmacies and March 19, 2025 for 503B outsourcing facilities. The semaglutide shortage was declared resolved on February 21, 2025, and the Fifth Circuit upheld that decision on August 27, 2026.

Since then the FDA has published a running count of problems with unapproved GLP-1 products. As of May 31, 2026 it had received 990 adverse-event reports for compounded semaglutide and more than 730 for compounded tirzepatide. The agency's page on unapproved GLP-1 drugs is the place to check for new alerts.

Compounded tirzepatide is still sold, at a month-1 median of $299 (range $149 to $470) across the 14 providers in the FormBlends price index on September 3, 2026, and a prescriber can still write for it on a patient-specific basis. But the legal footing is different from what this article described in April 2026, and a platform that still cites the shortage as its justification has not updated its own page in more than a year.

Counterfeit and research-use-only Zepbound: what the FDA and Lilly have actually said

Three documents, all dated. First, the FDA's February 26, 2025 warning letter to USApeptide.com: the site introduced unapproved and misbranded semaglutide and tirzepatide into interstate commerce, labeled them research use only while marketing them for human use, sold them without prescriptions, and omitted the boxed warning about thyroid C-cell tumors. Second, Lilly's counterfeit-safety page (seen September 5, 2026): counterfeit and research-use-only tirzepatide is sold online, on social media and at med-spas; counterfeits may contain the wrong ingredient or the wrong amount of it; and, citing the National Association of Boards of Pharmacy, only about 5% of roughly 35,000 active online pharmacies comply with U.S. pharmacy law. Lilly's number for reporting a suspected counterfeit is 1-800-545-5979. Third, the FDA's unapproved-GLP-1 page with the adverse-event counts above.

What we did not find, as of September 5, 2026, is an FDA alert about counterfeit Zepbound pens specifically; the FDA's counterfeit alerts so far concern Ozempic. That is not reassurance. A genuine Zepbound pen or vial comes from a U.S. pharmacy, LillyDirect or one of the sellers in the table above, with a prescription, a pharmacy label and a Lilly lot number. Anything sold without a prescription, priced far below $299, or labeled for research is not Zepbound.

The 2026 Zepbound savings card, corrected: $25 when covered, $499 when not

The savings-card section of this article was written against the 2024 card, which paid up to $550 a month. The 2026 card (terms seen September 4, 2026; expires December 31, 2026) works differently, and every $550 figure on this page has been replaced.

Your situation	What the 2026 card does
Commercial insurance that covers Zepbound	Pay as little as $25 per one-, two- or three-month fill; the card pays at most $100, $200 or $300 per fill and $1,300 per calendar year, across 13 fills
Commercial insurance that does not cover Zepbound	Pay $499 per one-month fill
Medicare, Medicaid, TRICARE or other government coverage	Not eligible (Medicare beneficiaries: see the $50 GLP-1 Bridge)
No insurance	Not eligible; use LillyDirect self-pay at $299 to $449

Because the covered-patient benefit is capped at $100 a month, a copay above $125 leaves you paying more than $25, and a copay above about $400 leaves you paying more than the $299 LillyDirect price for the starting dose. Run that arithmetic before assuming the card is the best route.

KwikPen vs single-dose pen vs vial: which one each channel sells

Zepbound comes in three containers, and which one you get depends on how you pay.

Form	Who sells it	Details
Single-dose pen (2.5 to 15 mg per 0.5 mL)	Retail and mail-order pharmacies billing insurance	The insurance-billed product, list about $1,086 a month; four pens per month; no measuring
KwikPen (multi-dose, e.g. 10 mg/2.4 mL)	LillyDirect, GoodRx-listed pharmacies, Ro, Walgreens, Amazon Pharmacy, the Medicare Bridge	Four weekly doses in one pen; $299 to $449 self-pay; WeightWatchers states it is not eligible for insurance coverage
Single-dose vial (2.5 to 15 mg per 0.5 mL)	LillyDirect (home delivery or Walmart pickup), TrumpRx routing	Drawn with a syringe; same $299 to $449 tiers; Lilly Medical Information (June 19, 2024) says the vial has no preservative, is single-dose, and splitting it into smaller doses is not recommended and has not been studied

Two consequences. If you want insurance to pay, you need the single-dose pen and a covered prescription. If you are paying cash, ask for the KwikPen or vial and a LillyDirect or GoodRx price, because a cash claim for single-dose pens at a pharmacy counter can still ring up near list.

FAQ

Where can I buy Zepbound without a prescription?

You cannot legally buy Zepbound without a prescription anywhere in the United States. Zepbound is a prescription medication that requires evaluation and approval by a licensed healthcare provider. Websites claiming to sell Zepbound without a prescription are operating illegally and likely selling counterfeit or unsafe products.

Can I buy Zepbound at Walmart or CVS?

Yes, if you have a prescription. Walmart, CVS, Walgreens, Rite Aid, and most retail pharmacies stock Zepbound. Your doctor sends the prescription to the pharmacy, the pharmacy processes your insurance claim, and you pick up the medication. If your insurance requires prior authorization, the process takes 3 to 30 days.

How much does Zepbound cost without insurance?

Without insurance, the cheapest brand route is LillyDirect self-pay: $299 a month for 2.5 mg, $399 for 5 mg and $449 for 7.5 mg and up (refilled within 45 days), as vials or KwikPens; GoodRx lists the KwikPen at $299 at Walgreens, CVS, Walmart and Costco (September 2026). Single-dose pens list at about $1,086. The Lilly savings card does not apply to uninsured patients. Compounded tirzepatide had a month-1 median of $299 (range $149 to $470) on September 3, 2026.

Can I use GoodRx or other discount cards for Zepbound?

Yes, and the number has changed. As of September 5, 2026 GoodRx lists the Zepbound KwikPen at $299 without insurance at Walgreens, CVS, Walmart, Costco, Sam's Club and Target, which matches LillyDirect's 2.5 mg self-pay price. GoodRx prices cannot be combined with insurance. The Lilly savings card brings a covered copay to as little as $25 per fill (caps of $100 to $300 per fill) and sets a $499 price when a commercial plan does not cover Zepbound.

Is compounded tirzepatide the same as Zepbound?

Compounded tirzepatide contains the same active ingredient as Zepbound (tirzepatide), but it is not FDA-approved and is not manufactured by Eli Lilly. Compounded tirzepatide is prepared by state-licensed compounding pharmacies in response to individual prescriptions. It is legal to compound tirzepatide while the medication remains on the FDA drug shortage list.

Can I buy Zepbound from Canada?

No. Importing prescription medications from Canada or other countries is illegal under federal law except in very narrow circumstances. The FDA does not inspect Canadian pharmacies, and you have no way to verify the medication is genuine. Stick to U.S.-licensed pharmacies and compounding facilities.

Does insurance cover Zepbound?

Some commercial insurance plans cover Zepbound, but most require prior authorization. Medicare Part D plans are not required to cover weight-loss medications, and most don't. Medicaid coverage varies by state. Check your plan's formulary or call your insurer to confirm coverage.

How long does Zepbound prior authorization take?

Prior authorization typically takes 7 to 10 business days, but can range from 3 days (fast track) to 30 days (if additional documentation is requested). Your doctor submits clinical documentation (BMI, comorbidities, previous weight-loss attempts), and the insurance company reviews the request.

What if my insurance denies coverage for Zepbound?

You can appeal (under federal rules the insurer must decide a prior-authorization appeal within 15 days, or 72 hours if urgent), use the savings card's $499 not-covered price if you have commercial insurance, buy self-pay Zepbound through LillyDirect at $299 to $449 a month, or switch to compounded tirzepatide (median $299 for month 1 as of September 3, 2026). If your plan covers semaglutide (Wegovy) but not tirzepatide, ask your doctor about switching to semaglutide.

Can I get Zepbound through a telehealth platform?

Telehealth platforms do not prescribe brand-name Zepbound. They prescribe compounded tirzepatide, which contains the same active ingredient. The medication is compounded by a U.S.-licensed pharmacy and shipped to your home. This option does not involve insurance; the FormBlends Compounded GLP-1 Price Index put the month-1 median at $299 (range $149 to $470) on September 3, 2026.

Is Zepbound available at all pharmacies right now?

Generally yes. The FDA declared the tirzepatide shortage resolved on December 19, 2024, so pharmacies can order every strength. A single store can still run out; ask about the KwikPen, try another location in the chain, or use LillyDirect home delivery or Walmart pickup, which Lilly launched in November 2025 at nearly 4,600 Walmart pharmacies.

Can I use the Lilly savings card if I'm on Medicare?

No. Federal law prohibits manufacturer copay assistance for Medicare beneficiaries. If you're enrolled in Medicare Part D, you cannot use the Lilly savings card. You'll pay your plan's Tier 3 or Tier 4 copay, which is often $300 to $500/month.

What's the difference between Zepbound and Mounjaro?

Both contain tirzepatide. Mounjaro is FDA-approved for type 2 diabetes. Zepbound is FDA-approved for chronic weight management. The medications are identical except for labeling and approved indication. Some insurance plans cover Mounjaro but not Zepbound, or vice versa.

Can I buy Zepbound online legally?

Yes, with a prescription. LillyDirect (Lilly's own program), Amazon Pharmacy, Ro and Walgreens Weight Management all ship or dispense genuine Zepbound after a prescriber's evaluation, at $299 to $449 a month for the KwikPen or vial as of September 2026. Any site that ships tirzepatide without a prescription, or labels it for research use, is selling an unapproved product; the FDA's February 26, 2025 warning letter to one such seller spells out why.

Is the Zepbound KwikPen covered by insurance?

As a rule, no. The KwikPen and the single-dose vial are Lilly's self-pay products, sold through LillyDirect and its partners at $299 to $449 a month; WeightWatchers' Zepbound page states plainly that the KwikPen is not eligible for insurance coverage. The insurance-billed product is the single-dose pen. The one exception is the Medicare GLP-1 Bridge, which covers the KwikPen at $50 a month from July 1, 2026 through December 31, 2027.

How much is Zepbound through Ro?

Ro sells the Zepbound KwikPen at Lilly's self-pay tiers, $299 for 2.5 mg, $399 for 5 mg and $449 for 7.5 to 15 mg, on top of a membership Ro quotes as low as $74 a month with annual prepayment (seen September 5, 2026). The 45-day refill rule applies: miss the check-in window and the higher doses rise to $499 to $699. A KwikPen holds four weekly doses and ships directly to you.

Can I pick up LillyDirect Zepbound at Walmart?

Yes. LillyDirect and Walmart announced on October 29, 2025 the first retail pickup option for LillyDirect self-pay Zepbound vials, live at nearly 4,600 Walmart pharmacies from mid-November 2025. The prices quoted at launch ($349 for 2.5 mg, $499 for other doses) have since been superseded by Lilly's current tiers of $299, $399 and $449 a month. You still need a prescription; the pickup replaces home delivery, not the prescriber.

Related guides

• How to Buy Zepbound: The Four Legal Purchase Pathways and What Each Actually Costs in 2026
• Where to Buy Ozempic: Every Legal Channel, What It Costs, and How to Verify the Pharmacy
• Where Can I Buy Ozempic: Every Legal Channel, the Shortage Reality, and What to Do When Your Pharmacy Says No
• Where Can I Buy Mounjaro: Every Legal Channel, Cost Breakdown, and What Most Patients Get Wrong About Access
• Where Can I Buy Zepbound in 2026: The Complete Channel Map from Retail Pharmacies to Compounded Tirzepatide
• How to Buy Wegovy in 2026: The Five Legal Pathways, What Each Costs, and Which One Works When Insurance Denies Coverage
• Tool: cost calculator

Sources

1. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
2. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Lancet. 2021.
3. FDA Drug Shortages Database. Tirzepatide injection. Accessed April 2026. Available at accessdata.fda.gov/scripts/drugshortages.
4. Conti RM et al. Prior authorization and access to GLP-1 receptor agonists for obesity. JAMA Health Forum. 2024.
5. FDA Safety Communication. Risk of counterfeit semaglutide products. October 2023.
6. Federal Food, Drug, and Cosmetic Act, Section 503A. Pharmacy compounding. 21 U.S.C. § 353a.
7. American College of Gastroenterology. Guidelines for the diagnosis and management of gastroesophageal reflux disease. 2022.
8. Lilly USA. Zepbound prescribing information. November 2023.
9. Lilly USA. Zepbound Savings Card terms and conditions. 2024.
10. Centers for Medicare & Medicaid Services. Medicare Part D coverage of anti-obesity medications. 2024.
11. National Association of Boards of Pharmacy. Internet pharmacy warning signs. 2025.
12. U.S. Customs and Border Protection. Importing prescription drugs for personal use. 2025.
13. Davies MJ et al. Gastric emptying and glycemic control with tirzepatide. Diabetes Care. 2023.
14. Eli Lilly. LillyDirect Zepbound self-pay pricing, seen September 4, 2026. https://www.lilly.com/lillydirect/zepbound
15. GoodRx. Zepbound prices and coupons, seen September 5, 2026. https://www.goodrx.com/zepbound
16. Ro. Zepbound through Ro, seen September 5, 2026. https://ro.co/weight-loss/zepbound/
17. Walgreens. Zepbound through Walgreens Weight Management, seen September 5, 2026. https://www.walgreens.com/topic/virtual-healthcare/weight-loss/zepbound.jsp
18. TrumpRx. Zepbound vial, seen September 5, 2026. https://trumprx.gov/p/zepbound
19. Walmart. LillyDirect and Walmart Pharmacy launch first retail pick-up option for Zepbound, October 29, 2025. https://corporate.walmart.com/news/2025/10/29/lillydirect-and-walmart-pharmacy-launch-first-retail-pick-up-option-with-direct-to-consumer-pricing-for-zepbound
20. GLP Chart. Amazon Pharmacy GLP-1 program, updated August 31, 2026. https://glpchart.com/program/amazon-pharmacy/
21. WeightWatchers. Zepbound through Med+, seen September 5, 2026. https://www.weightwatchers.com/us/weight-loss-medication/zepbound
22. WeightWatchers. How much does Zepbound cost? March 11, 2026 (list price $1,086.37). https://www.weightwatchers.com/us/blog/weight-loss/zepbound-cost
23. Eli Lilly. Zepbound coverage and savings card terms, 2026 program year, seen September 4, 2026. https://zepbound.lilly.com/coverage-savings
24. healthinsurance.org. Does health insurance cover drugs used for weight loss? Seen September 4, 2026. https://www.healthinsurance.org/faqs/does-health-insurance-cover-drugs-used-for-weight-loss-such-as-ozempic-wegovy-mounjaro-and-zepbound/
25. FDA. Tirzepatide injection shortage resolved, December 19, 2024, with compounding enforcement dates. https://www.fda.gov/media/185577/download
26. FDA. FDA's concerns with unapproved GLP-1 drugs used for weight loss, adverse-event counts as of May 31, 2026. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
27. FDA. Warning letter to USApeptide.com, February 26, 2025. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/usapeptidecom-696885-02262025
28. Eli Lilly. Counterfeit and unapproved medicines safety page, seen September 5, 2026. https://www.lilly.com/medicines/safety/counterfeit
29. Eli Lilly Medical Information. Can the Zepbound (tirzepatide) vial be split into smaller doses? Last updated June 19, 2024. https://medical.lilly.com/us/products/answers/can-the-zepbound-tirzepatide-vial-be-split-into-smaller-doses-241673
30. Eli Lilly. Zepbound prescribing information, revised 08/2026 (dosage forms, no DEA schedule). https://pi.lilly.com/us/zepbound-uspi.pdf
31. KFF. Medicaid coverage of and spending on GLP-1s, January 16, 2026. https://www.kff.org/medicaid/medicaid-coverage-of-and-spending-on-glp-1s/
32. HealthCare.gov. Internal appeals deadlines, seen September 5, 2026. https://www.healthcare.gov/appeal-insurance-company-decision/internal-appeals/
33. FormBlends. Compounded GLP-1 Price Index feed, as of September 3, 2026. https://formblends.com/feeds/glp1-prices.json

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound, Mounjaro, Wegovy, Ozempic, Saxenda, and Rybelsus are registered trademarks of their respective owners. GoodRx is a registered trademark of GoodRx Holdings, Inc. CVS, Walgreens, Walmart, and Rite Aid are registered trademarks of their respective owners. Express Scripts, OptumRx, and Caremark are registered trademarks of their respective parent companies. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.